Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,689 recruiting studies in this area right now.
By phase
- Not applicable9,836
- Phase 24,475
- Phase 12,738
- Phase 1/Phase 21,689
- Phase 31,406
- Phase 2/Phase 3282
- Phase 4263
Top conditions
- Breast Cancer1,231
- Prostate Cancer659
- Cancer658
- Colorectal Cancer495
- Lung Cancer430
- Ovarian Cancer338
- Multiple Myeloma330
- Gastric Cancer300
- Pancreatic Cancer298
- Acute Myeloid Leukemia293
- Hepatocellular Carcinoma286
- Solid Tumor258
- Advanced Solid Tumor256
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer205
- Advanced Solid Tumors196
- Esophageal Cancer195
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University312
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- National Cancer Institute (NCI)288
- Mayo Clinic236
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca132
- University Health Network, Toronto126
Where studies are running
- California1,427
- Texas642
- Arizona513
- Florida443
- Alabama421
- New York412
- Massachusetts340
- Maryland328
- New Jersey268
- Pennsylvania240
Recruiting studies20,689 total
- NCT05753839Recruiting
Testing surgery plus immunotherapy for metastatic kidney cancer
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
SeoulAges 18 years+ - NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT05754203Recruiting
Radiation plus immunotherapy for advanced lung cancer
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05754840RecruitingPhase 1/Phase 2
Cannabinoid treatment for children with hard-to-treat cancers
This early-phase study tests whether a cannabinoid medicine (including nabilone/cannabis-based treatment) can be given safely to children and teens with relapsed or refractory cancer. It may help with treatment options for children whose cancer has come back or did not respond to standard therapy.
Vancouver, British ColumbiaAges 4–18 - NCT05754892Recruiting
Using tumor lab markers during adrenal cancer care
This trial studies how to use lab tests (“molecular markers”) in routine clinical care to help manage people with adrenal tumors that could be cancerous. If you are having surgery soon (or recently), your tissue may be tested to see if these markers improve decision-making for your care.
ParisAges 18 years+ - NCT05755113RecruitingPhase 2
Testing a drug injected into tumors for soft tissue sarcoma
This trial tests whether a medicine injected directly into a tumor can shrink or control advanced soft tissue sarcoma. It mainly looks for people whose tumors can be safely injected with a hand exam or ultrasound.
New York, New YorkAges 18 years+ - NCT05755672Recruiting
Study biomarkers during curative-intent treatment for metastatic colon cancer
This study looks at biological markers (substances measured in the body) during treatment for metastatic colorectal cancer. It may help doctors better understand how treatment works, using patients who are treated with a goal of cure.
Lund, Skåne CountyAges 18–110 - NCT05756777RecruitingPhase 1
Gilteritinib plus other IDH medicine for relapsed AML
This Phase 1 study tests how well gilteritinib works when combined with either ivosidenib or enasidenib in adults with relapsed or refractory acute myeloid leukemia (AML). It targets specific genetic changes in the leukemia and may help shrink or control the cancer when standard options haven’t worked.
Basking Ridge, New JerseyAges 18 years+ - NCT05756023Recruiting
IVF and ICSI outcomes in women with PCOS
This trial studies how IVF (fertility treatment) and ICSI (a lab step used with IVF) work in women with PCOS. It may help doctors understand which PCOS-related factors affect success and how to tailor care.
AsyutAges 20–35 - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05756985Recruiting
Providing fresh brain tissue to better understand glioblastoma
This study aims to improve understanding of glioblastoma (and gliosarcoma) by preserving live, usable brain-tissue samples during brain surgery. If you’re having repeat tumor surgery or your scans suggest these cancers, the study may ask to collect tissue for research.
Miami, FloridaAges 18 years+ - NCT05757336RecruitingPhase 2
Study drug mix for unresectable gallbladder cancer
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
ShanghaiAges 18–75 - NCT05757817Recruiting
New flap surgery for mouth or throat cancer reconstruction
This trial studies whether a new surgical reconstruction method can improve outcomes for people with oral cavity or oropharyngeal squamous cell carcinoma (a type of head and neck cancer). The goal is to rebuild the area using a tissue flap while reducing problems where the tissue is taken from.
MontpellierAges 18 years+ - NCT05758389RecruitingPhase 2
Immunotherapy plus chemo for locally advanced head and neck cancer
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Nanjing, JiangsuAges 18–75 - NCT05758610RecruitingPhase 1
Study drug test for relapsed or hard-to-treat AML and NHL
This Phase 1 trial tests ETH-155008, a new medicine, in adults with relapsed or refractory acute myeloid leukemia (AML) or non-Hodgkin lymphoma (NHL). It’s mainly designed to see how the treatment works in the body and whether it may help when standard treatment isn’t available or hasn’t worked.
Zhengzhou, HenanAges 18 years+ - NCT05758688RecruitingPhase 2
Proton radiation after surgery for uterine or cervical cancer
This trial studies whether proton beam radiation after surgery can better treat certain uterine (endometrial) or cervix (cervical) cancers. It may help by targeting the pelvic area while limiting radiation to nearby organs.
Voorhees Township, New JerseyAges 18 years+ - NCT05759793RecruitingPhase 1
CAR T trial for relapsed myeloma targeting GPRC5D
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
ShanghaiAges 18–75 - NCT05760612RecruitingPhase 3
After breast cancer surgery, test neratinib plus trastuzumab
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
GuangzhouAges 18–70 - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05760391Recruiting
Check anti-PD-1 therapy plus radiation for advanced esophageal cancer
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
ShanghaiAges 18–80 - NCT05761054Recruiting
Pre-surgery radiation to shrink soft-tissue sarcoma
This trial studies giving radiation before surgery to help control a soft-tissue sarcoma while keeping surgery as less extensive as possible. It may help shrink the tumor and improve what the surgeon can remove.
Florence, FiAges 18 years+ - NCT05761093Recruiting
Share your treatment preferences for metastatic prostate cancer
This study asks people with metastatic prostate cancer and their doctors about what benefits and risks matter most when choosing treatment. Your answers can help improve how treatment options are discussed in Hong Kong.
ShatinAges 18 years+ - NCT05761366RecruitingPhase 2
18F-PSMA PET/CT scan for PSMA-positive tumors
This Phase 2 study tests an imaging scan called 18F-PSMA PET/CT to find tumors that have a specific marker (PSMA). It may help doctors better locate and evaluate PSMA-positive cancers.
Beijing, ChaoyangAges 18 years+ - NCT05763277Recruiting
Predicting early response to atezolizumab plus bevacizumab
This study tries to predict how well your cancer responds early after starting a treatment called atezolizumab plus bevacizumab. If you qualify, your information may help doctors choose better treatments sooner for people with advanced liver cancer.
SeoulAges 18–80
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,689 recruiting oncology studies from the U.S. registry right now, out of 31,955 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.